<DOC>
	<DOC>NCT01686620</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of BIOD-123 compared to insulin lispro (Humalog®) when used as part of a basal-bolus regimen in patients with type 1 diabetes.</brief_summary>
	<brief_title>A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Established clinical diagnosis of type 1 diabetes, consistent with ADA classification criteria (Diabetes Care 35: S64S71, 2012), for more than 1 year. Age: 18 years old, or older. Body Mass Index: between 18 and 35 kg/m2, inclusive. Willing to use insulin glargine as the only basal insulin throughout the duration of the trial. Willingness not to use insulin pump treatment and only use the study glucose meter and CGM devices during the duration of the trial. History of known hypersensitivity to any of the components in the study medication Treatment with pramlintide or GLP1 analogs within 30 days of screening or anticipated use of these medications during the course of the study. Treatment with oral or intravenous corticosteroids in the last 3 months prior to screening. Standard doses of inhalational corticosteroid used as part of a long term treatment regimen are allowed. Consistent recent hypoglycemic unawareness within the last six months History of more than two severe hypoglycemic events within six months prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Mealtime insulin</keyword>
	<keyword>Ultra-rapid acting insulin</keyword>
	<keyword>Prandial insulin</keyword>
</DOC>